Trials / Completed
CompletedNCT04469673
A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Efficacy, as Well as Immunogenecity, Pharmacokineticks and Pharmacodynamics of Multiple Doses of JS002 on Stable Statin Therapy in Patients With Hyperlipidemia.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Biological：JS002 | Administered by subcutaneous injection |
| BIOLOGICAL | Placebo | Administered by subcutaneous injection |
Timeline
- Start date
- 2019-05-23
- Primary completion
- 2020-05-03
- Completion
- 2020-06-28
- First posted
- 2020-07-14
- Last updated
- 2020-07-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04469673. Inclusion in this directory is not an endorsement.